These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27858316)

  • 1. Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells.
    Daniels MW; Brock GN; Wittliff JL
    Breast Cancer Res Treat; 2017 Jan; 161(2):245-258. PubMed ID: 27858316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.
    Sereff SB; Daniels MW; Wittliff JL
    J Clin Lab Anal; 2019 Nov; 33(9):e22982. PubMed ID: 31359505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Genes for Methylxanthine Pathway-Associated Enzymes Accompanied by Sex Steroid Receptor Status Impacts Breast Carcinoma Progression.
    Wittliff JL; Sereff SB; Daniels MW
    Horm Cancer; 2017 Dec; 8(5-6):298-313. PubMed ID: 28971320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
    Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
    Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
    Yau C; Benz CC
    Breast Cancer Res; 2008; 10(4):R61. PubMed ID: 18631401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer.
    Omar M; Harrell JC; Tamimi R; Marchionni L; Erdogan C; Nakshatri H; Ince TA
    Breast Cancer Res; 2024 Sep; 26(1):132. PubMed ID: 39272208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
    Liu D
    Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment.
    Tang J; Cui Q; Zhang D; Liao X; Zhu J; Wu G
    J Cell Mol Med; 2019 Aug; 23(8):4980-4990. PubMed ID: 31124293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status.
    Andres SA; Wittliff JL; Cheng A
    Horm Cancer; 2013 Aug; 4(4):208-21. PubMed ID: 23568563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
    Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
    Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
    Keshgegian AA; Cnaan A
    Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.
    Laas E; Mallon P; Duhoux FP; Hamidouche A; Rouzier R; Reyal F
    PLoS One; 2016; 11(2):e0148957. PubMed ID: 26895349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
    Oh DS; Troester MA; Usary J; Hu Z; He X; Fan C; Wu J; Carey LA; Perou CM
    J Clin Oncol; 2006 Apr; 24(11):1656-64. PubMed ID: 16505416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.